*
*
Scoring Key: 5=Strongly Agree 4= Somewhat agree 3=Neither agree nor disagree 2= Somewhat disagree 1=Strongly disagree NA=Not applicable
54321NA
The skills learned in this CME course enhanced my professional competence.
The skills learned in this CME course will be applied in the treatment of my patients.
*
5 = High level of confidence 4 = Moderately high level of confidence 3 = Average level of confidence 2 = Low level of confidence 1 = No level of confidence NA|Not applicable to my practice
54321
Properly diagnose and manage advances in chordoma.
Apply targeted agents, in re-irradiation versus systemic therapy for recurrent gliomas.
*
Scoring Key: 5=Strongly satisfied 4= Somewhat satisfied 3=Neither satisfied nor dissatisfied 2= Somewhat dissatisfied 1=Strongly dissatisfied
54321
Molecular Characterization and Prognostication in Gliomas: Are we there yet? - Jose Otero, M.D.
Standard of Care and Limitations of Imaging for Gliomas - Kevin Abrams, M.D.
Exploring Therapeutic Vulnerabilities in Gliomas - Vinay K. Puduvalli, M.D.
Molecular Risk Stratification of Meningiomas - David R. Raleigh, M.D., PhD
Advanced Imaging for CNS Tumors - William Breen, M.D.
Current Standard of Care and Advances in Chordoma - Matthew Hall, M.D.
Brachytherapy for CNS Tumors - Michael McDermott, M.D., FAANS
Fractionation for Brain Metastases Scott Soltys, M.D.
Single Fraction SRS for Brain Metastases William Breen, M.D.
Re-irradiation for Recurrent Gliomas Scott Soltys, M.D.
Systemic Therapy for Recurrent Gliomas Yazmin Odia, M.D., M.S., FAAN
Observation for WHO Grade 2 Meningiomas David R. Raleigh, M.D., PhD
Radiation for WHO Grade 2 Meningiomas - C. Leland Rogers, M.D.
Changing Paradigm in CNS Lymphoma - Yuliya Linhares, M.D.
Syndromic Primary CNS Tumors - Nicole Ullrich, M.D., Ph.D.
Global Perspectives on CNS Germ Cell Tumors - Mohamed S. Abdelbaki, M.D.
Protons & Neurocognition Protection for Pediatric Brain Tumors - Torunn Yock, M.D.
*
*
*
*
*
*
*
*